Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed Childhood Standard-Risk B-Cell ALL of Average or High Risk of Relapse By Ogkologos - January 13, 2025 734 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COG AALL1731 study Source RELATED ARTICLESMORE FROM AUTHOR AI-Supported Mammography Screening Shows Favourable Outcomes Compared with Standard Double Reading FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up MOST POPULAR 2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’ January 17, 2022 EMA Recommends Extension of Therapeutic Indications for Lisocabtagene Maraleucel February 28, 2025 Chris Pratt Partners with GreaterGood to Support Food Banks and Feed... December 18, 2020 FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma June 24, 2022 Load more HOT NEWS Early-onset cancer: why are more young adults being diagnosed? Adding Avelumab to Preoperative Chemoradiotherapy Provides Promising Anti-Tumour Activity in Locally... Cervical screening in Wales extended to every 5 years: Why the... 2020 Cancer Incidence and Mortality in EU-27 Countries
